

Case Number	Manufacturer	Case entry (date)	Age (years)	Sex	Dose	Date of symptoms	Interval between vaccine/symptoms (days)	Interval between symptoms/hospital admission (days)	Platelet lowest value	Dimer-d high value	Thrombosis topography	Anti-PF4 Elisa	Functionl Platelet Activating Assay (with added PF4)	Desfecho	Classificaçã o Brighton TTS	Experts Haematologists panel UK
1	AstraZeneca	2021-03-29	23	Female	first dose	2021-03-27	0	NA	147.000	1.119	Lungs	not detectable	not detectable	Recovered	Level 1	Possible
2	AstraZeneca /Fiocruz	2021-05-05	35	Female	first dose	2021-05-01	9	2	20.000	16.000	CVST + bleeding/ Limbs	detectable	NA	Death	Level 1	Definite
3	AstraZeneca /Fiocruz	2021-05-07	35	Female	first dose	2021-04-30	7	6	22.000	20.000	Haemorrhagic stroke/placenta	detectable	detectable	Death	Level 1	Definite
4	AstraZeneca /Fiocruz	2021-05-15	56	Male	first dose	2021-05-08	4	0	17.000	41.000	CVST + bleeding/ limbs	detectable	detectable	Death	Level 1	Definite
5	AstraZeneca /Fiocruz	2021-05-21	60	Male	first dose	2021-05-13	8	7	24.000	32.070	Haemorrhagic stroke	detectable	NA	Death	Level 1	Probable
6	AstraZeneca /Fiocruz	2021-05-28	63	Female	first dose	NA	NA	NA	15.000	20.000	Portal vein	NA	NA	Recovered	Level 1	Probable
7	AstraZeneca	2021-05-31	39	Female	first dose	2021-05-29	7	3	101.000	9.500	CVST + bleeding	detectable	NA	Death	Level 1	Definite
8	AstraZeneca /Fiocruz	2021-05-31	63	Male	second dose	2021-05-09	4	0	125.300	32.070	Lungs/limbs	not detectable	not detectable	Recovered	Level 1	Probable
9	AstraZeneca	2021-05-31	40	Male	first dose	2021-05-29	9	0	28.000	40.800	Coronary	not detectable	NA	Recovering	Level 1	Probable
10	AstraZeneca /Fiocruz	2021-06-02	66	Female	first dose	2021-05-08	11	4	9.000	NA	Limbs/CVST + bleeding	NA	NA	Death	Level 1	Possible
11	AstraZeneca /Fiocruz	2021-06-07	34	Female	first dose	2021-06-01	8	3	38.000	95.160	CVST + bleeding	not detectable	NA	Death	Level 1	Probable
12	AstraZeneca /Fiocruz	2021-06-11	24	Female	first dose	2021-05-28	7	NA	2.000	11.400	CVST	detectable	NA	Recovered	Level 1	Definite
13	AstraZeneca /Fiocruz	2021-06-14	55	Female	first dose	2021-05-23	11	0	30.000	24.000	Limbs/lungs	detectable	NA	Recovered	Level 1	Definite
14	AstraZeneca /Fiocruz	2021-06-14	29	Male	first dose	2021-05-16	3	7	58.000	NA	Haemorrhagic stroke	NA	NA	Death	Level 3	Improbable
15	AstraZeneca /Fiocruz	2021-06-14	52	Male	first dose	2021-05-30	11	12	23.000	NA	Haemorrhagic stroke	NA	NA	Death	Level 1	Possible
16	AstraZeneca /Fiocruz	2021-06-28	45	Female	first dose	2021-06-16	5	NA	75.000	6.958	CVST	detectable	detectable	Recovered	Level 1	Definite

Case Number	Manufacturer	Case entry (date)	Age (years)	Sex	Dose	Date of symptoms	Interval between vaccine/symptoms (days)	Interval between symptoms/hospital admission (days)	Platelet lowest value	Dimer-d high value	Thrombosis topography	Anti-PF4 Elisa	Functionl Platelet Activating Assay (with added PF4)	Desfecho	Classificaçã o Brighton TTS	Experts Haematologists panel UK
17	AstraZeneca /Fiocruz	2021-07-16	46	Female	first dose	NA	NA	NA	27.000	3.600	Limbs	detectable	NA	Recovered	Level 1	Probable
18	AstraZeneca /Fiocruz	2021-07-08	86	Male	second dose	2021-06-04	3	10	23.000	18.470	Lungs, ischemic stroke	NA	NA	Death	Level 1	Probable
19	AstraZeneca /Fiocruz	2021-07-19	59	Female	first dose	2021-04-17	7	6	46.000	NA	Limbs	NA	NA	Recovered	Level 1	Possible
20	AstraZeneca /Fiocruz	2021-07-09	47	Female	first dose	2021-06-30	8	4	28.000	NA	CVST +bleeding	NA	NA	Death	Level 1	Possible
21	AstraZeneca /Fiocruz	2021-07-02	42	Female	first dose	2021-06-11	14	NA	47.000	10.000	Limbs	not detectable	not detectable	Recovering	Level 1	Possible
22	AstraZeneca /Fiocruz	2021-08-09	57	Female	first dose	2021-06-26	11	2	67.000	14.210	Limbs/CVST	detectable	NA	Recovered	Level 1	Probable
23	AstraZeneca /Fiocruz	2021-08-09	75	Female	second dose	2021-07-03	35	8	79.000	NA	Portal vein/ mesenteric vein	not detectable	NA	Recovered	Level 1	Possible
24	AstraZeneca /Fiocruz	2021-08-13	33	Male	first dose	2021-07-22	0	12	93.000	69.227	CVST	detectable	detectable	Death	Level 1	Definite
25	AstraZeneca /Fiocruz	2021-08-13	37	Female	first dose	2021-08-03	11	0	19.000	122.858	CVST + bleeding	detectable	NA	Death	Level 1	Definite
26	AstraZeneca /Fiocruz	2021-06-09	35	Female	first dose	2021-05-10	10	0	15.000	NA	Ischemic Stroke	NA	NA	Death	Level 1	Possible
27	AstraZeneca	2021-09-14	28	Male	first dose	2021-08-23	9	NA	113.000	NA	hemorrhagic stroke	detectable	detectable	Death	Level 1	Possible
28	AstraZeneca	2021-09-24	28	Female	first dose	2021-09-09	9	10	86.000	NA	splenic/ mesenteric vein	detectable	detectable	Death	Level 1	Probable
29	AstraZeneca /Fiocruz	2021-08-31	38	Male	first dose	2021-08-01	10	0	45.000	NA	CVST + bleeding	detectable	detectable	Recovering	Level 1	Definite
30	AstraZeneca /Fiocruz	2021-11-04	NA	Female	first dose	2021-08-20	8	2	22.000	4.000	Hemorrhagic Stroke	detectable	detectable	Death	Level 1	Probable
31	AstraZeneca /Fiocruz	2021-08-20	36	Male	first dose	2021-07-31	10	7	8.000	115.000	Portal/splenic/ mesenteric vein	NA	NA	Death	Level 1	Probable

Case Number	Manufacturer	Case entry (date)	Age (years)	Sex	Dose	Date of symptoms	Interval between vaccine/symptoms (days)	Interval between symptoms/hospital admission (days)	Platelet lowest value	Dimer-d high value	Thrombosis topography	Anti-PF4 Elisa	Functionl Platelet Activating Assay (with added PF4)	Desfecho	Classificaçã o Brighton TTS	Experts Haematologists panel UK
32	AstraZeneca /Fiocruz	2021-11-04	23	Female	second dose	2021-08-30	5	0	34.000	1.200	Limbs	not detectable	not detectable	NA	Level 1	Possible
33	AstraZeneca /Fiocruz	2021-11-04	58	Male	first dose	2021-06-10	0	NA	46.000	20.000	Esplenic vein	not detectable	not detectable	NA	Level 1	Possible
34	AstraZeneca /Fiocruz	2021-11-04	44	Male	first dose	2021-06-02	0	NA	112.000	9.580	Limbs	not detectable	not detectable	Recovering	Level 1	Probable
35	AstraZeneca /Fiocruz	2021-10-15	39	Female	NA	2021-07-03	NA	0	62.000	NA	Lungs	not detectable	not detectable	Recovering	Level 1	Possible
36	AstraZeneca /Fiocruz	2021-11-04	54	Female	first dose	2021-07-12	37	NA	43.000	2.370	Limbs	not detectable	not detectable	Recovering	Level 1	Possible
37	Janssen	2021-07-14	42	Male	first dose	2021-07-07	8	8	38.000	128.000	CVST+bleeding	detectable	detectable	Death	Level 1	Definite
38	Janssen	2021-08-03	38	Male	first dose	2021-07-26	11	0	10.000	71.272	CVST+bleeding	detectable	detectable	Death	Level 1	Definite
39	Pfizer/Biontech	2021-08-25	37	Female	first dose	2021-08-17	20	0	30.000	4.625	Limbs	not detectable	not detectable	NA	Level 1	Probable

NA: not available

CVST: Central Venous Sinus Thrombosis